{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP005 Research and Development Informed Consent 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT INFORMED CONSENT"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP005"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th16 January 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th15 January 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "04/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "17th January 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: November 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP005 Research and Development Informed Consent 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 11,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Fiona McNeela"
                    },
                    {
                        "text": "Clinical Trials Research Nurse"
                    },
                    {
                        "text": "04/07/2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "SOP-01- SOP on SOPs SOP-04- Trial Master File (TMF) SOP-06- Research Staff Training 04080 Consent to Examination or Treatment Policy"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "17th January 2020"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Applicable to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Equality impact assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2: Key points of ICH GCP guidance on informed consent Appendix 3: Preliminary equality analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff that consent participants into research studies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It aims to provide clear guidance on the legal requirements and the procedures of taking informed consent when recruiting patients to research studies carried out by MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "The Sponsor shall ensure a valid informed consent was obtained prior to patients participating in research to meet ethical and regulatory requirements. Prior to trial initiation, the Sponsor should ensure that the study has received R&D confirmation from MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Informed consent is a process by which a trial participant voluntarily confirms his or her willingness to participate in a research study after being duly informed of all aspects of the trial including the risks and benefits to the participant, alternative options, peripheral and altruistic nature of the research. The process should be carried out in stages, allowing sufficient time for the participant to understand oral and written information (e.g. patient information sheet) and to clarify any arising queries. The subjects must be informed that they are free to withdraw at any point in the trial after consenting if they wish to do so."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "Informed consent is at the heart of ethical research. All studies involving individuals must have appropriate arrangements for obtaining consent, and the ethics review process pays particular attention to those arrangements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "Freely given informed consent should be obtained from every participant prior to clinical trial participation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "The principle of International Conference of Harmonisation Good Clinical Practice (ICH GCP) state that in obtaining and documenting informed consent, Investigators"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "text": "should comply with the applicable regulatory requirement(s), and adhere to GCP. Sponsor/Principal Investigator shall ensure before starting a trial to obtain a written approval/favourable opinion from ethics committee for the written informed consent form and any other written information to be provided to the subjects. The Sponsor shall also ensure that the research study has R&D confirmation from MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 2.5,
                "text": "Before subjects can participate in research a valid informed consent must be obtained by the research team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee involved (including those with an honorary research contract or letter of access) with clinical research sponsored by MEHT including, but not limited to Unit Heads, Chief Investigators (CI), Principal Investigators (PI), Co-investigators, Consultants, Clinical Trial Pharmacists, Research Managers, Statisticians, Research nurses, Research Midwives, Allied Health Professionals, Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "Coordinators, R&D Department & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Sponsor shall ensure that a valid informed consent was obtained for all subjects before recruitment and prior to carrying out any study specific procedures. Consent must be taken by the CI/PI or other individuals designated by PI."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The Sponsor or a person designated by the Sponsor should fully inform the subject or, if the subject is unable to provide informed consent, the subject's legal representative, of all pertinent aspects of the trial including the written information given approval/favourable opinion by the ethics committee."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The CI/PI shall ensure that subjects have fully understood what they are consenting to. The Sponsor shall maintain overall responsibility for the consenting process."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "Sponsor/Investigator may delegate parts of the informed consent duties to appropriately trained and qualified members of the research teams. Staff delegated to consenting shall have a valid GCP certificate. Delegation shall be documented on the study delegation log held in the trial master file (TMF). For non-CTIMP studies, it is recommended that staff delegated to consenting should have completed a GCP training session."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "The research personnel directly involved in the consenting process must personally sign and date the consent forms. They must also make a record in the patient's medical notes, of discussions related to the clinical trial with the patient and any further contact. If appropriate, the CI/PI may sign/countersign the consent form. All personnel who have completed/signed a consent form must have completed the study delegation log, which shall be countersigned/dated by the CI/PI. The CI/PI or delegated individual should also ensure that patient information sheets contain contact details for nominated personnel within the research team. The patient should also be followed up after being given information as to their decision to take part in the study and this should provide an opportunity for any further questions to be discussed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 4.6,
                "text": "All research personnel with consenting responsibility shall ensure that the original copy of the research consent form is held in the Trial Master File (TMF)/ Investigator Site File (ISF). Copies of signed consent form may be held in the Medical Notes and/or TMF and a copy must be provided to the patient. Staff must also ensure appropriate recording of all informed consent discussions in the patient medical records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Considerations Before Starting Clinical Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 The Sponsor/PI shall provide copies of all written informed consent forms and any other written information e.g. Patient Information Sheet (PIS) to the R&D Office. All subsequent versions must be submitted to the R&D office as substantial amendments."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 All written informed consent forms and any other written information e.g. PIS must have approval from ethics. All subsequent versions must also receive ethics approval as substantial amendments. Blank copies of all versions should be held in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "5.1.3 None of the written information relating to the trial shall unduly influence or coerce the trial subject or subject's legal representative."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "5.1.4 The written information shall be in a non-technical language, easily understandable to the trial subject or the subject's legal representative or the impartial witness. It is recommended that the template provided by HRA/REC must be consulted during the preparation stages."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "5.1.5 The Sponsor/PI shall ensure that the study teams are adequately trained in obtaining and documenting a valid informed consent. Particular training needs must be met in describing technical languages involved in complex interventions, unlicensed IMP, invasive assessment methods, randomisation and other trial methodologies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "5.1.6 In order to obtain consent, the delegated staff member shall be familiar with the protocol, risks and benefits associated with the study and the peripheral and altruistic nature of the research. The delegated staff member shall be effectively trained in communicating all aspects of the study in a non-technical and understandable language."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "5.1.7 The PI must ensure teams are adequately trained in clearly documenting the consenting process in patient records and other trial related documentations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "5.1.8 The Sponsor/PI must ensure R&D confirmation from BTUH is in place for the research study before patients are consented."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Obtaining Informed Consent from Trial Subjects"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "5.2.1 Consenting patients shall be carried out in stages, allowing sufficient time between each stage. Stages shall include preliminary discussion, further discussion & provision of written information (PIS) and final consent."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 The subject must be allowed sufficient time between each stage for understanding the provided oral and written information. The original research consent forms should be held within the TMF/ISF. A copy should be held within the patient's medical notes and a copy provided to the patient."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "5.2.3 Under emergency situation, the consenting methods may vary. If prior consent from the patient was not available, the subject's legal representative must be consulted. If neither the subject nor the legal representative was available, the subject maybe enrolled as described in the protocol and/or elsewhere. This must be supported with documented approval from the ethics committee, to protect the rights, well-being and safety of the trial participants. The Investigator shall abide by institutional policies and regulatory compliance."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "5.2.4 In order to obtain a valid informed consent, the following best practice guidelines shall be considered:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Early discussion with patients"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Answering questions fully by a qualified member of the research team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Providing adequate information to make an informed decision"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Patient must not be under any pressure or duress"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Patient must be competent to make an informed decision"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Make sufficient notes of all discussions in patient's notes"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Patient information sheets should be used to enhance the patient's understanding of research however should not be used as a substitute for discussion"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "5.2.3 The Sponsor/PI must ensure overall control for the informed consent process. However, the PI may delegate parts of the consenting process to adequately trained and qualified personnel. The Investigator shall ensure that the delegated responsibilities are documented, dated and signed by the nominated personnel and a confirmation signature from the Investigator in a \u2018delegation of responsibilities log'. A copy shall be retained in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "5.2.4 The PI shall ensure that a written informed consent form was signed and personally dated by the subject or subject's legal representative."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "5.2.5 An explanation of the standard treatment shall be provided to the Subject prior to detailed discussions of experimental research (Clinical Trials). The subject shall be fully informed that their level of standard care shall not be affected irrespective of whether they decide to participate in research study or not."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "5.2.6 The written information sheet and the informed consent verbal discussion shall contain the key points included in ICH GCP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "5.2.7 The subject or legal representative shall be provided with written information such as the patient information sheet and any other relevant materials to read at their own pace."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "5.2.8 Further information sessions shall be setup to allow discussion with the patient and to encourage questions. This may be in the form of an outpatient appointment or a telephone call. These discussions should also be annotated in the patient's medical record. The Investigator should ensure subjects fully understand all aspects of the research study including what the subject's responsibilities are."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "5.2.9 If the patient's first language is not English, provisions for translational service must be considered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.2.10 If consent was taken from minors or incapacitated adults, several other criteria must be considered. Please refer to relevant Guidance and other applicable paediatric regulations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "5.2.11 Obtaining consent is an ongoing process and if the research study protocol or any patient information sheets contain significant amendments (e.g. significant issues with regards to patient's safety), subjects may in some cases need to be re- consented. This shall be determined by the Sponsor and Ethics Committee."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-01- SOP on SOPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-04- TMF"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "\u25cf gSOP-06- Research Staff Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "\u25cf HRA guidance on information sheets and consent forms"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 1,
                "text": "ICH GCP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals (Refer to appendix 3)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Product (IMP)  means a pharmaceutical form of an active substance or placebo being tested, or to be tested, or used, or to be used, as a reference in a clinical trial, and includes a medicinal product which has a marketing authorization but is, for the purposes of the trial\u2014"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorization,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "b) used for an indication not included in the summary of product characteristics under the authorization for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "c) used to gain further information about the form of that product as authorised under the authorization;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 1,
                "text": "Investigator Site File (ISF)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "text": "The file(s) held at each site taking part in the trial which hold the essential trial document set necessary for local approval and trial conduct at site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "text": "Patient Information Sheet (PIS) - A document that explains all relevant study information to assist the trial participant in understanding the expectations and requirements of participation in a clinical trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "text": "Site File - Site Files are held by the Principal Investigator at sites and contain copies of the essential  documents,  local  approvals, signed  consent forms  and  completed  data forms."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became  effective  on  the  1st  May   An amendment to  implement  Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File - The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Key points of ICH GCP Guidance on Informed Consent"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "This document refers to the ICH GCP Guidance on informed consent of trial subjects. Key points are listed below:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subjects shall be provided with what the trial involved, explanation of the parts that are experimental and other relevant background information."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Why the subject/legal representative was approached and the purpose of the trial and eligibility criteria."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject/legal representative must be ensured that the trial participation and related activities will be confidential. However, subjects should be informed that their medical records and other trial related documents will be accessed by research staff and other related personnel such as regulatory authorities, monitors, auditors and ethics committee for verification of trial data. The subject must authorise such access in the form of written consent, personally signed and dated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An explanation of the trial treatment(s), details of any medications, details of any invasive procedures, and the probability of random assignment to each treatment. If a placebo or use of medication outside licensed indication was involved, the subject should be provided with clear explanation of what that entails."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An explanation of foreseeable risks or inconveniences to the subject and, where applicable, to any embryo, foetus, or nursing infant."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An explanation of the expected benefits and altruistic nature of research must be provided. If the subject was not to gain any clinical benefit from the study, this should be explained."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject/legal representative should be made aware of any available alternatives and the risks/benefits related to these."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An explanation of compensation and/or care and supporting treatment available to the subject in the event of trial related injury must be explained."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The anticipated prorated payment or travel expenses, if any, to the subject for participating in the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An explanation for use and storage of the collected biological samples (e.g. blood, tissue) must be provided. Appropriate use of these and supporting written consent must be obtained in compliance with the Human Tissue Act."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject/legal representative must be advised that the trial participation is voluntary and that the subject may refuse to take part or to stop participation in the trial at any time."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subject must be informed of their responsibilities of participation in a trial, the duration of the trial, the likely number of trial participants, and the responsibilities for reporting any adverse events to the study team immediately to ensure their safety and that of other participants. If applicable, the subjects must be advised to provide the emergency card during every hospital admission to alert the study team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subjects must be provided with details of the study team and an emergency contact number."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subjects must be informed that they will be provided with up-to-date information of all trial related issues and if necessary, the protocol and/or patient information sheets may be amended. In some cases, the subject may need to be re-consented. The subject should be provided with copies of all up-dated consent forms and PIS."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Subjects must be informed that following consent, under certain cases, they might not be able to continue with the trial. If they failed to meet eligibility criteria at a later stage following diagnostic tests or other foreseeable circumstance and/or reasons under which the subject's participation in the trial may be terminated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "Research and Development Informed Consent/MEHTSOP005/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "Research and Development Informed Consent/MEHTSOP005/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research and Development Informed Consent/ MEHTSOP005"
            }
        },
        {
            "type": "table",
            "sequence_num": 124,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "image",
            "sequence_num": 126,
            "data": {
                "url": "MEHTSOP005 Research and Development Informed Consent 1.0.003.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 127,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 13.0,
                "text": ""
            }
        }
    ]
}